Chairs: Chris Cannon (US), Sam Dagogo-Jack (US) Faculty: David Cherney (CAN), Ildiko Lingvay (US) 14:30 – 14:35 Opening Remarks Chairs 14:35 – 14:45 Ertugliflozin and VERTIS CV – New Data Expanding Our Understanding for the Treatment of Patients With Type 2 Diabetes and Cardiovascular Disease Sam Dagogo-Jack (US) 14:45 – 14:55 Recent Data on the Efficacy and Safety of Ertugliflozin Using Insulin in Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease Ildiko Lingvay (US) 14:55 – 15:05 The Latest VERTIS CV Heart Failure Results – Adding to Our Clinical Understanding From a Cardiologist’s View 15:05 – 15:15 New VERTIS CV Kidney Protection Results – Adding to Our Clinical   Understanding From a Nephrologist’s View David Cherney (CAN) 15:15 – 15:28 What Does It All Mean For Our Patients? A Cross-Specialty Faculty Roundtable Discussion Faculty 15:28 – 15:30 Closing Remarks Chairs

Program Chair’s Introduction and Welcome
Applying Sensor‐Based Technology to Optimize Blood Glucose Time-in-Range (TIR) and Health Metrics Across the Comprehensive Spectrum of Diabetes Care: Establishing a New, Guideline- and Evidence-Based Standard of Care for Persons with Diabetes

Session 1
Applying Sensor-Based Glucose Monitoring and Telemedicine to Optimize Real World Impact and Diabetes Management in the Age of Covid-19 and Beyond—What Have the Studies Taught Us? How Do We Apply Them to Diabetes Practice Now?

Session 2
A Practical Roadmap for Using Registry Data and Trial-Based Evidence to Guide Use of Sensor‐Based, Glucose Monitoring: Focus on Results from National Diabetes Registries (NDRs) to Optimize Multi-Dose Insulin (MDI) Therapy in Persons with Diabetes

Session 3
Translating Guidelines and Meta‐Analysis Trials to Guide Practical Aspects of Diabetes Care: Using Sensor-Based Glucose Monitoring to Improve Time in Range (TIR), GMI and AGP for Persons with Diabetes on Non-Insulin Regimens

Program Chair’s Summary and Vision Statement
The Foundational Role of Sensor‐Based Glucose Monitoring Technology — How Should Clinicians and Patients Collaborate to Maximize Blood Glucose Time in Range and Improve Safety and Health Outcomes in Persons with Diabetes?

Chair: Jiten Vora (UK)
Co-Chair: Nayyar Iqbal (AstraZeneca)

14:30  – 14:35


Elisabeth Björk (AstraZeneca)
Jiten Vora (UK)
Nayyar Iqbal (AstraZeneca)

14:35  – 14:50

Role of water conservation and metabolism in SGLT2 inhibitor mediated organ protection

Jens Marc Titze

14:50  – 15:10

Cracking the code in CKD: Mechanisms of renoprotection

Hiddo Heerspink

15:10  – 15:30

SGLT2 inhibitors in HF: Piecing together the puzzle of preserved ejection fraction

Sanjiv Shah (USA)

15:30  – 15:40

Panel discussion

All faculty

15:40  – 15:55

State of art lecture:  NASH, disease burden and new opportunities – Emerging new modalities to manage NASH

Arun Sanyal (USA)

15:55  – 16:00

Closing remarks

Regina Fritsche-Danielson (AstraZeneca)
Jiten Vora (UK)

14:30 – 14:35


Chair: Tina Vilsbøll (Denmark)

14:35 – 14:47

Should we have a more holistic treatment approach to improve healthy lifespan in people living with T2D?

Vanita Aroda (USA)

14:47 – 15:10

Panel discussion

Vanita Aroda (USA)
Melanie Davies (UK)
John Buse (USA)
Nikolaus Marx (Germany)

15:10 – 15:20

Treatment intensification in T2D with high-dose semaglutide: SUSTAIN FORTE

Juan Pablo Frias (USA)

15:20 – 15:25

Questions from the audience


15:25 – 15:27

Welcome back

Chair: Tina Vilsbøll (Denmark)

15:27 – 15:35

The potential of semaglutide 2.4 mg for weight management

Rachel Batterham (UK)

15:35 – 15:45

Changing the paradigm in obesity care: the STEP 1–4 data

Melanie Davies (UK)

15:45 – 15:55

The clinical impact of double-digit weight loss

John Wilding (UK)

15:55 – 16:08

Questions from the audience


16:08 – 16:10

Thanks and wrap-up

Chair: Tina Vilsbøll (Denmark)

16:30 – 16:35


Chair: Tina Vilsbøll (Denmark)

16:35 – 16:45

Insulin innovations – the past: journey so far

Andreas Liebl (Germany)

16:45 – 16:55

Insulin innovations – the present: current scenario

Lena Landstedt-Hallin (Sweden)

16:55 – 17:05

Patient case study

Andreas Liebl (Germany)

Lena Landstedt-Hallin (Sweden)

17:05 – 17:20

Insulin innovations – the future: roadmap to the future

Ronald Goldenberg (Canada)

17:20 – 17:28

Panel discussion


17:28 – 17:30

Thanks and wrap-up

Chair: Tina Vilsbøll (Denmark)

19:00 – 19:05


Chair: Tina Vilsbøll (Denmark)

19:05 – 19:30

Highlights and learnings: current diabetes and obesity management and future opportunities


09:15 – 09:20

Overview of oral semaglutide and PIONEER trials

Filip K Knop (Denmark)

09:20 – 09:30

Case scenarios based on clinical evidence

Filip K Knop (Denmark)
Vanita Aroda (USA)

09:30 – 09:35

Patient-centric practicalities

Vanita Aroda (USA)

09:35 – 09:45

A patient-centered approach with oral semaglutide

Panel discussion and Q&A (live)


17:40 – 17:45

The case challenge
Teaming up to tackle cardiorenal risk in diabetes

Melanie Davies (UK)

17:45 – 17:55

Defining treatment goals: SGLT2i, implications from clinical trials and guidelines

Nikolaus Marx (Germany)

17:55 – 18:05

Practical Challenges: SGLT2i in the spectrum of diabetes, CVD & CKD: Who and how to manage?

Melanie Davies (UK)

18:05 – 18:10

Discussion How to overcome clinical inertia?

Nikolaus Marx (Germany)
Melanie Davies (UK)




Educational objectives

  • To summarise the epidemiology and pathophysiology of patients with diabetes, CVD and CKD
  • To discuss the role of SGLT2 inhibitors, in a risk-based intervention strategy that targets glucose control and cardiorenal risk
  • To address the remaining questions on the role of SGLT2 inhibition in the management of patients with diabetes and cardiorenal complications
  • To provide an expert perspective on the clinical management of patients with type 2 diabetes, CKD and CV

17:40 – 17:55

obesity, weight loss and CV risk

Kim Connelly (Canada)

17:55 – 18:10

STEPping forward:
cardiovascular risk factors in patients with overweight or obesity

Ildiko Lingvay (USA)

18:10 – 18:25

STEPping into the future:
managing cardiovascular outcomes in people with overweight or obesity

Subodh Verma (Canada)

18:25 – 18:40

Live Q&A

Chaired by Kim Connelly (Canada)


  • Associate Professor Neale Cohen FRACP
    Head Clinical Diabetes
    Baker Heart and Diabetes Institute
  • Dr Martin de Bock FRACP PhD
    Paediatric Endocrinologist
    University of Otago and Canterbury District Health Board

Supported by a Medical Education Grant from Gan & Lee

Vilsbøll, Tina (Denmark)
Heinemann, Lutz (Germany)

19:30 – 19:33IntroductionVilsbøll, Tina (DNK)
19:33 – 19:43Biosimilar Insulin Manufacturing:
Why the process IS the product?
Heinemann, Lutz (GER)
19:43 – 19:53Why do patient and HCP perceptions about
biosimilar insulin matter?
Home, Philip (UK)
19:53 – 20:00Discussion and closureAll


18:30 – 18:32


Athena Philis-Tsimikas (USA)
Simon Heller (UK)

18:32 – 18:35

A retrospective look:
100 years since insulin was discovered

Simon Heller (UK)

18:35 – 18:47

Once-weekly basal insulins:
From innovation to RCTs

Athena Philis-Tsimikas (USA)

18:47 – 18:53

Patient-centric care:
How once-weekly options may help get patients to target

Simon Heller (UK)

18:53 – 18:58

Questions from the audience

Facilitated by:

Athena Philis-Tsimikas (USA)
Simon Heller (UK)

18:58 – 19:00


Athena Philis-Tsimikas (USA)
Simon Heller (UK)

Four experts in primary care, endocrinology, cardiology and nephrology will come together to discuss a patient-centred and evidence-based approach to care in T2D after metformin, offering their clinical perspectives on the optimal and multifactorial management of an evolving patient case


  • John Buse (chair, USA)
  • Kate Stevens (UK)
  • Nikolaus Marx (Germany)
  • Naresh Kanumilli (UK)

Chairs: Ofri Mosenzon (ISRAEL), Rich Pratley (US)

Faculty: Chris Cannon (US), David Cherney (CAN)

18:30- 18:33                Opening Remarks

(3 min)                        Speakers: Chairs (US)


18:33-18:41                  ‘Highlighting the Patient with Diabetes and Cardiometabolic Disease’

(8 min)                        Speaker:  Rich Pratley (US)


18:41 – 18:49              ‘Answering Unmet Needs – Clinical Understanding of Recent Heart Failure Data for Patients with Diabetes and Cardiovascular Disease’

(8 min)                        Speaker: Chris Cannon (US)


18:49 -18:57                ‘Adding to the Clinical Understanding for Patients with Diabetes and Cardio-renal Disease’

(8 min)                        Speaker: David Cherney (CAN)


18:57 – 19:27              ‘A Cross-Specialty Faculty Roundtable on Meeting the Needs of Patients with Diabetes and Established Cardiometabolic Disease: Are SGLT2is Best Utilized as a Cardiovascular Drug? A Kidney Drug? A Glycemic Lowering Agent? Or All of the Above?’

(30 Min)                      Speakers: Faculty


19:27 – 19:30              Closing Remarks

(3 min)                         Chairs

Supported by an unrestricted educational grant from Amarin Pharma, Inc.

18:30 – 18:35

Welcome, Introductions, Program Overview

Dirk Müller-Wieland

18:35 – 18:55

New Clinical Evidence of Omega-3 Fatty Acids on ASCVD Event Reduction

Dirk Müller-Wieland

18:55 – 19:15

Real-world Clinical Implications on Reducing ASCVD Events

Handrean Soran

19: 15 – 19:30

Panel Discussion and Q&A

Handrean Soran

Dirk Müller-Wieland

Closing Comments

Dirk Müller-Wieland
Handrean Soran

Learning Objectives

At the conclusion of this activity, learners should be better able to:

  • Describe the spectrum of large-scale outcomes trials of omega-3 fatty acids on ASCVD events.
  • Appreciate the differences between omega-3 fatty acids and their formulations to impact ASCVD events, including the negative role of dietary supplements.

Chair: Jiten Vora (UK)

Speakers: TBC

Time (CEST)



(5 min)

Welcome and introductions

Jiten Vora

(10 min)

Addressing unmet needs in CKD and T2D with nonsteroidal MR antagonists


(15 min)

MR antagonism confers benefits irrespective of anti-diabetic agents or metabolic status: Insights from FIDELIO-DKD


(15 min)

FIGARO-DKD: Expanding the benefit of MR antagonism in CKD and T2D


(10 min)


All faculty


(5 min)

Summary and close

Jiten Vora

Chair – Prof Matthias Laudes

Speakers – Prof Francesco Giorgino, Prof Vaia Lambadiari



  • Welcome and introduction (Prof Matthias Laudes)
  • Diagnosis of severe insulin resistance and atypical diabetes and when to suspect lipodystrophy (Prof Francesco Giorgino)
  • The management of lipodystrophy: clinical challenges and treatment opportunities (Prof Vaia Lambadiari)
  • Q&A, conclusions (Prof Matthias Laudes)


09:15 – 09:35

How and why to identify high-risk patients: lessons from the clinic

Elmar Jaeckel (Germany)
Lise Lotte Gluud (Denmark)

09:35 – 09:45

The future of NASH: the importance of interdisciplinary collaboration (interactive Q&A)

Elmar Jaeckel (Germany)
Lise Lotte Gluud (Denmark)

Faculty:  David Cherney (CAN), Kim Connelly (CAN), Samuel Dagogo-Jack (US)

18:15- 18:20                Opening Remarks

(5 min)                        Speaker: Sam Dagogo-Jack (US)



18:20 – 18:43              ‘Cross-talk between the Heart, Kidneys & the Endocrine System – Understanding

(23 min)                       for Type 2 Diabetes and Cardiorenal Disease’                    


Speakers: David Cherney (CAN), Kim Connelly (CAN), Samuel Dagogo-Jack (US)

18:43- 18:45               Closing Remarks

(2 min)                        Speaker: Sam Dagogo-Jack (US)

Supported by an independent educational grant from Novo Nordisk.

This activity is intended for diabetologists/endocrinologists, primary care physicians and cardiologists.

18:15 – 18:30

The Endocrinologist in the Lead

The Right Drug for the Right Patient at the Right Time

18:30 – 18:45

The Cardiologist in the Lead

Primary and Secondary Cardiovascular Protection

18:45 – 19:00

The Primay Care Physician in the Lead

Implementing Proactive Diabetes Care across the Stages

19:00 – 19:15

Panel Discussion and Q & A




Supported by an independent educational grant from Lilly.

This activity is intended for diabetologists/endocrinologists and PCPs

08:15 – 08.25

Better Metabolic Health with Incretin-based Therapies – Achievements and Ambitions

08:25 – 08:40

The Power of novel dual GIP/GLP-1 Receptor Agonists 

08:40 – 09:00

The Clinical Evidence for GIP/GLP-1 Receptor Agonists – Assessing the Emerging Profile

09:00 – 09:15

Panel Discussion and Q & A



17:40 – 17:43


Adie Viljoen (UK)

17:43 – 17:51

Early treatment: what are the benefits of early initiation of GLP-1RAs?  

Tina Vilsbøll (Denmark)
Juris Meier (Germany)

17:51 – 18:01

Discussion session 1

Tina Vilsbøll (Denmark)
Juris Meier (Germany)

18:01 – 18:09

Spotlight on: type 2 diabetes management for those with renal impairment

Tina Vilsbøll (Denmark)
Peter Rossing (Denmark)

18:09 – 18:19

Discussion and Q&A

Tina Vilsbøll (Denmark)
Peter Rossing (Denmark)

18:19 – 18:27

Spotlight on: glycaemic management in individuals with T2D and CVD

Matt Cavender (USA)
David Strain (UK)

18:27 – 18:37

Discussion session 2

Matt Cavender (USA)
David Strain (UK)

18:37 – 18:40

A look at what is up and coming

Adie Viljoen (UK)